Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance by unknown
a SpringerOpen Journal
Sahu et al. SpringerPlus 2014, 3:695
http://www.springerplus.com/content/3/1/695REVIEW Open AccessAdverse drug reactions monitoring: prospects
and impending challenges for pharmacovigilance
Ram Kumar Sahu*, Rajni Yadav, Pushpa Prasad, Amit Roy and Shashikant ChandrakarAbstract
Pharmacovigilance plays a consequential role in the surveillance of adverse drug reactions, which is provoked by
the drugs used to cure diseases. Adverse drug reactions (ADRs) produce detrimental or undesirable effects to the
body after administration of drugs. It has been reported that the number of patients dying because of contrary
effects of drugs per year increased upto 2.6-fold. Moreover, rates of hospitalization of patients are increasing owing
to adverse effects of drugs. Thus, it becomes challengeable for physician, health care providers, WHO and
pharmaceutical industries to resolve the associated problem of ADRs. During the clinical trial of a novel drug, it is
prominent to explore the dependability of drug. In this review, we documented the details required to identify the
ADRs in patients along with reported banned drugs.
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World Health Organization (WHO) defines that adverse
drug reactions (ADRs) are noxious and unwanted effects
produced by the drug, when it is applied for the ailment of
disease or diagnosis (Shukla et al. 2012). The most common
examples of drugs that produce ADRs include paracetamol
and nimesulide (hepatotoxic effects) (Rehan et al. 2002).
It is a well-known fact that no drug is completely free
from side effects. The European commission proclaimed
ADRs (Rishi et al. 2012; Rehan et al. 2002) till date are
referred in Table 1.
Before executing any new drug in the market, its clin-
ical trial and safety database are validated for the safety
profile of the drug. In various countries, whether devel-
oped or developing, the issue of ADRs is accepted to ef-
fortlessly, and thus it becomes a prime duty to develop
awareness among patients about ADRs.
When a novel drug’s safety is under process, it is being
constantly supervised by pharmacovigilance centres for the
identification of adverse effects of the drug, if any (Beard
1992; Mishra and Kumar 2013). According to WHO, phar-
macovigilance is a set of practices aiming at the identifica-
tion, understanding and assessment of risks associate with
drugs. Moreover, they take steps to control the adverse effect
of drugs. Pharmacovigilance starts from the pre-marketing* Correspondence: ramsahu79@yahoo.co.in
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in any medium, provided the original work is pof new drugs and continues through the post-marketing of
drugs (Lazarou et al. 1998).
There are a bunch of examples of drugs, which have
been detached as well as outlawed from the European
market owing to reported adverse effects of drugs. Rosigli-
tazone holds the first position in the market; other
well-known drugs including terfenadine, cisapride, phenyl-
propanolamine, rofecoxib, cerivastatin, gatifloxacin, cisa-
pride, sibutramine and tegaserod were withdrawn because
of their adverse reactions. For every drug in the market,
the adverse events, if any, should be inspected in detail,
and the facts should be conveyed to the people or public
for elucidation of the information (Hampton 2005; Lisa
et al. 2003; Lazarou et al. 1998).
In contemplation to supply the news for effective drug
use in population, which includes different groups of pa-
tients, such as elderly, children and diseased patients, an
adequate information regarding drug’s adverse effects is
required, which is achieved by a successful pharmacovigi-
lance programmes run on that drug (Gupta and Udupa
2011; Santosh and Tragulpiankit 2002).
Pharmacovigilance plays several roles such as recogni-
tion, observation, assessment and documentation of drug
based problems and understanding the factors producing
adverse effects (Ravi Shankar et al. 2006; Rohilla et al.
2012). Here we tried to summarize about ADRs, and how
it can be monitored by pharmacovigilance to minimizeOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 ADRs report according to European Commission
Impact
Patient’s report Percentage reported
Patients admitted in hospital 0.3% - 5%
Patient’s death reported 3.5%
Patient’s reported with ADR during
their hospital stay
1.9% -6%
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vide adverse events about ADRs along with the complete
information of medication errors.Proclamations of adverse effects of drug
The USFDA data disclosed that adverse effect of drugs
increased almost two times in the endmost decade. It
has been noticed that significant sum of patients were
pegged out because of fervent adverse effects of drugs.
This report has been authenticated in the 10th issue of
the Archives of Internal Medicine (Livio et al. 2012;
Doheny 2009; Aeries 1995). The number of reports per
annum proliferated upto 2.6-fold from 1998 to 2005. In
1998, the numbers of adverse events proclaimed were
34,966, which increased to 89,842 by 2005.
The number of drugs in the market producing ADRs
is documented in Table 2.
Scientific data indicated that different drugs were banned,
and some were detached owing to the adverse effects in pa-
tients (Tables 3 and 4).Documentation of ADRs
The pharmacovigilance curriculum conveyed worldwide
to motivate that all suspected drug-related adverse
events should be outlined. It takes interests on reports
of the following:
(A) Every adverse effect suspected or occurred by new
drugs and drugs of current issue.
(B) Documentation of various drugs that caused ADRs,
which include death, life-threatening conditions,
disability, hospitalization and congenital
abnormalities.
The significant adverse reaction of any drug should be
notified within seven days. The other facts related to ad-
verse events should be informed within eight days (Bates
et al. 1995; Classen et al. 1997). The ADR form can be col-
lected through any pharmacovigilance centre. The filled
ADR form can be submitted to the peripheral pharmacov-
igilance centre. After reviewing the form, the centre
forwards it to the regional centre and after that it is pro-
pelled to the zonal centre (Goldman 1998; Palaian et al.
2006; Ravi Shankar et al. 2010). The details are thenstatistically inspected and forwarded to WHO-Uppsala
Monitoring Committee (UMC).Procedure for reporting ADRs
It is the first duty of any pharmacovigilance centre to re-
port all suspected adverse events of the drug if found. In-
formation regarding ADRs and the type of ADRs that
should be reported are tabulated in Table 5.Monitoring of ADRs
ADR monitoring is spelled out as the practice of continu-
ously monitoring the undesirable effects caused using any
drug. Pharmacovigilance plays an imperative imperson-
ation in monitoring ADRs (Hall et al. 1995; Hornbuckle
et al. 1999; Juntti and Neuvoren 2002).
It is inherent for pharmaceutical regulators to screen their
pharmaceutical products in the market and record if any
suspected adverse reactions are identified. ADRs can occur
by use of various pharmaceutical products, herbal drugs,
cosmetics, medical devices, biological, etc. The introducing
of this monitoring procedure intends at warranting that pa-
tients receive safe and beneficial medicinal products (Karch
and Lasagna 1997).
If any of the adverse events are not stated it may result
in noxious and serious effects of remedial products. Thus,
properly conducting ADR monitoring programmes will
help to reduce the harmful effects of therapeutic products
(Kessler 1993).Benefits of ADR monitoring
An ADR monitoring and reporting programme can fur-
nish following benefits:
1. It caters information about quality and safety of
pharmaceutical products.
2. It initiates risk-management plans.
3. It prevents the predictable adverse effects and helps
in measuring ADR incidence.
4. It instructs health care team, patients, pharmacists
and nurses about adverse drug effects and creates
awareness regarding ADRs.
The main objective of ADR monitoring is to disclose
the quality and frequency of ADRs and to identify the risk
factors that can cause the adverse reactions (Moore 2001;
Murphy and Frigo 1993).ADR monitoring includes different studies for the
identification of adverse events
Case reports
By this method, the unpredictable (bizarre) effects i.e.
TYPE-B adverse drug reactions are reported.
Table 2 List of drugs causing ADRs
Marketed
drug
Type of dosage form Patients
affected
Side effects References
Oxycodone Tablet- film coated and
extended release
5% Constipation, nausea, somnolence, dizziness, pruritis,
vomiting, sweating, asthenia, dry mouth, headache
(Purdue 2009)
Fentanyl IV , patch 7.9% Skin reactions, respiratory depression, mental changes,
stroke
(Pasero 2005; Mohammed
2012) (Peng and Sandler
1999, Prommer 2009)
Clozapine Tablets 2.7% Cardiotoxicity, fever, chills, bodyache, flu symptoms,
mouth-throat ulcers, cough, sore throat, rapid heart rate,
rapid and shallow breathing.
(Cole et al. 2009)
Methadone Tablets 3.6% Respiratory depression, QT prolongation, lacrimation,
chilling, rhinorrhea, tachycardia, cramps, anorexia,
nausea, dilated pupils, fluching
(Kung et al. 2008) (Minino
et al. 2002)
Morphine Injection 3% Constipation, addiction, asphyxia, respiratory depression,
renal failure, slow heartbeat, increase in B.P.
(Haupt and Jeste 2006)
Acetaminophen Capsules 1.5% dark urine, loss of appetite, jaundice, damage to liver
and death, difficulty in breathing, swelling of face and
lips
(Huismen et al. 2002)
Ethanercept Syringe and subcutaneous
injection
0.18% Injection site pain, erythema reaction, rheumatoid
arthritis, vestibular neuritis
(Orlando and Perkins 2002)
Risperidone Tablets 1.6- 1.7% Stroke, heart failure, pneumonia, irregular heartbeat,
seizure, white patches and sore in lips
(Holford 1986)
Paclitaxel Injectionand vials 0.01-
0.06%
Blurred vision, black stools, painful urination, ulcers,
sores, red spots on skin, urticaria
(Orlando and Perkins 2002)
Paroxetine Tablets 0.9% Bone pain, serious ventricular arrhythmias, agitation,
hallucinations, tremors, increase in muscle tone
(Thisted et al. 1986)
Rofecoxib Tablets 2-3% Increased arrhythmias, abdominal pain, tenderness, or
discomfort, nausea, blood while vomiting, bloody, black,
or tarry stools, unexplained weight gain, swelling or
water retention, fatigue or lethargy, skin rash, itching,
yellowing of skin or eyes, flu-like symptoms, or unusual
bruising or bleeding.
(Krumholz et al. 2007)
Warfarin Tablets 1.2 -2.3% Fatal bleeding, stroke, heart attack, abdominal pain,
crawling, numbness, increase in menstrual flow, vaginal
bleeding, paralysis, shortness of breath, diarrhea, skin
blisters, hemorrhage, necrosis, purple toe syndrome
(Holbrook et al. 2005)
Celecoxib Capsules 1% Risk of GI ulcerations, bleeding perforations, coronary
artery disorder, cellulitis, angina pectoris, deep thrombo
phlebritis, myocardial infarction, pneumonia, unstable
angina
(Halpern 2005)
Atorvastatin Tablets 37 deaths Liver damage, loss of appetite, allergic pruritis, muscles
and joint pain, tendon problems, tiredness, jaundice
(Gaudreault et al. 1982)
Misoprostol Tablets 5-6% Abortion, miscarriage, GI bleeding, multi organ failure,
acute pain, haemodynamic instability, oesophageal
necrosis, cardiac arrest, resuscitation efforts, birth defects
(Fu et al. 1998)
Thalidomide Capsules 10% Somnolence, haematuria, urticaria, asthenia, pulmonary
embolism, heart failure, bradycardia, tachycardia, cardiac
arryhmias, deep vein thrombosis, seizures, orthostatic
hypotension, birth defects (phocomelia)
(Ito et al. 2010)





Hypoglycemia (may result fatal if severe), low BP,
irritability, fast heartbeat, convulsions, blurred visions
(FDA 2009)
Aspirin Tablets 25% Excess acid secretion, stomach cramps, haemorrhage,
bronchospasm, hepatitis interstitial, nephritis,
inflammation of skin, allergic, abnormal liver




Tablets 3- 3.9% Myocardial infarction, fatal stroke, death from vascular
events, hypertension, congestive heart failure, ulceration,
bleeding from stomach, coronary artery blockage
(He et al. 2005; Solomon
et al. 2004)
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Table 2 List of drugs causing ADRs (Continued)
Ciprofloxacin Tablets– extended release
tablets oral suspension
0.65- 1.2% High BP, angina, paroxysmal supraventicular tachycardia,
prolonged QT interval, blood clot in brain, hepatitis,
interstitial nephritis, migraine
(Carlo and Francesco 1978)
Gentamicin Tablets, cream, ointments,
injectable
– Severe kidney failure, nerve damage, permanent hearing
loss, agitation, stomach pain, blood in urine, chest pain,
stroke, coma, hallucinations, mental changes




Slow heartbeat, abnormal heart rhythm, Low blood
pressure, Inability to have an erection, hallucinations,
involuntary quivering, difficult urination, nervous,
confused, heart burn, diarrhea
(Delini et al. 2007)
Fluoxetine Capsules, tablets, liquids 0.014-
0.62%
Severe blistering, peeling and red skin rash, uneven
heartbeats, tremors, overactive reflexes, hallucination
and seizures
(Michael and Ma 2006)
Tetrabenazine Tablets 0.5% only
on
overdose
Neuroleptic malignant syndrome, irregular heartbeats,
parkinsonism, tardive dystonia, stroke sometimes, purple
patches, mental changes, tightness in chest, shortness
of breath, sore throat
(Jankovic and beach 1997)
Propofol Injectable 0.6-1.2% Severe hypotension, bradycardia, pulmonary edema,
systole, cardiac arrest, ventricular arrhythmias, respiratory
acidosis, dysponea, bronchospasm
(Douketis et al. 2007)
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This kind of reporting comes through reports of individual
doctors when a patient suffers from the particular effect.Impulsive reporting system
This method is considered as the most efficient method.
Mostly, all ADR reporting programmes follow this
method. Here, the effects are recorded spontaneously.
With this method, both unusual and acute ADRs can be
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skin or eyes, flu-like s
bleeding.Intensive monitoring studies
Health care members continuously watch the patients
and record all the events observed when a drug or dif-
ferent drugs are administered. In this, defined groups of
patients are screened to detect ADRs. The main disad-
vantage of these studies is that the population includes
the minimum patients and each patient is studied for
the concise period of time. Special investigations can be
performed if statistical screening is incorporated in this




omach pain, light coloured stools,
skin, fainting, dizziness, abdominal
r itchiness, prolongation of QT interval,
ostatic hypertrophy, acute hepatitis,
jaundice, hepatic dysfunction
0.9-1.2% (Ito et al. 2010)
sion, chronic angina, rhinitis, leg edema,





h, cardiac arrest, QT prolongation,
ventricular arrhythmias, cardiac
dia, hypotension
1-2% (Minino et al.
2002)
lsions, irregular heartbeat, QT







s, abdominal pain, tenderness, or
lood while vomiting, bloody, black, or
ed weight gain, swelling or water
lethargy, skin rash, itching, yellowing of
ymptoms, or unusual bruising or
2-3% (He et al. 2005)
(Solomon et al.
2004)
Table 4 Records of drugs withdrawn after ADRs observed in patient
Marketed drug Dosage form Withdrawn due to Patient’s
effected
References
Gatifloxacin Tablets, injectables Causes hyperglycemia and liver damage 1.2% (Carlo and Francesco
1978)
Phenylpropanolamine Microcapsules, tablets, sustained
release tablets




Capsule, tablet film coated Caused fatal heart rhythm abnormalities 0.8% (Delini et al. 2007)
Sibutramine Capsule Increased cardiovascular risk 0.2% (Schluter 1989)
Tegaserod Tablets Causes increased risk of heart attack 0.6% (Marx 2006)
Nimesulide (below
13 years age)
Tablets, oral suspension, gel,
suppositories
Caused life threatening hepatotoxic effects 1.3% (Gaudreault et al.
1982)
Cisapride Tablets, oral suspension, capsules,
medi-melt tablets, injections
Risk of cardiac arrhythmias 0.03% (Solomon et al. 2004)
Thalidomide Capsules Risk of teratogenicity 6-8% (Ito et al. 2010)
Temafloxacin Tablets Caused allergic reactions and
haemolyticanaemia
0.002- 0.04% (Delini et al. 2007)
Alpidem Tablet- film coated, Proved to be hepatotoxic 0.6% (Gaudreault et al.
1982)
Tolrestat (Alredase) Withdrawn not available Proved as severe hepatotoxic agent Not available (Schonthal et al.
2003)
Terfenadine (Seldane) Tablet withdrawn Caused cardiac arrhythmias 1.2% (Orlando and Perkins
2002)
Mibefradil (Posicor) Tablets Reported to cause drug interaction 123 death in
1 year
(Holford 1986)
Tolcapone Tablets Hepatotoxic in nature Not available (Delini et al. 2007)
Astemizole Tablet Interaction with other drugs 0.2% (Holbrook et al. 2005)
Troglitazone Showed to be hepatotoxic 0.009% (Solomon et al. 2004)
Cisapride Tablets, oral suspension, capsules,
medi-melt tablets, injections
Caused cardiac arrhythmias 80 deaths
during clinical
trial
(Solomon et al. 2004)
Trovafloxacin Oral tablets Liver failure cases reported 0.4% (Ito et al. 2010)
Cerivastatin Tablets Caused rhadomyolysis Not available (Chyka et al. 2007)
Rofecoxib (Vioxx) Tablets Myocardial infarction were reported 2-3% (He et al. 2005)
(Solomon et al. 2004)
Valdecoxib (Bextra) Tablets Heart attack and stroke occurred 0.8% (Halpern 2005)
Tegaserod (Zelnorm) Tablets Cardiovascular ischemic events occurred
followed by heart attack and stroke
0.03% (Marx 2006)
Aprotinin Tablets, injection Death occurred Not available (Marx 2006)
Thioridazine Tablets Cardio toxicity occurred by its use Not available (Marx 2006)
Sibutramine Capsule Cardiovascular risk increases by its use 0.2% (Schonthal et al.
2003)
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In these studies, patients administering similar medi-
cines are identified, and their events are recorded. Major
drawbacks of this method are that minimum patients
are included and no control group is present for com-
parison. The contingent examinations are too expensive,
and these investigations are difficult to perform on
newly marketed drugs (Nissen and Wolski 2007).Case–control studies (Retrospective Studies)
In these studies, patients who have illness or disease due
to the use of a drug are investigated to check if they have
taken the drug. These patients are then compared with a
matched control group that is similar in confounding
factors but do not possess the adverse events or illness.
This is a useful method in determining whether the drug
has caused the adverse event or not. However, by this
Table 5 Details required for reporting ADR events
Elements in
ADR reporting
Necessary information Others References
What should
be reported







medical practitioners or health care professionals, doctors, nurses, pharmacists,
assistants, pharmaceutical technicians, pharmaceutical assistants, clinical officers
and other health care providers
Manufacturers, all government




When it can be
reported
Any adverse reactions if noticed should be reported as soon as possible. – Ravi Shankar
et al. 2010




Fully filled completely ADR form should be submitted to pharmacovigilance
center
– Palaian et al.
2006
Sahu et al. SpringerPlus 2014, 3:695 Page 6 of 9
http://www.springerplus.com/content/3/1/695method, new ADRs cannot be identified (Parthasarathi
et al. 2007).
Case cohort studies
These studies include both prospective cohort study and
retrospective case–control studies; in other words, it is
the combination of both the studies (Pearson et al.
1994).
Record linkage
In this method, all the records such as prescription re-
cords, patient records and hospital records are studied
to identify the illness with drugs.
Meta analysis
It is a quantitative examination of two or more inde-
pendent studies to determine the overall effect and to
describe reasons in variation of study results (Prosser
and Kamysz 1990).
Utilitization of resident’s statistics
If a drug-induced event is very frequent and if suspicions
arise for them, case–control and experimental cohort
studies shall be initiated (Rao 2010).
Roles of pharmacovigilance in monitoring ADRs
Many incidents occurred that caused the need of laws
and regulations regarding the safe use of drugs. After
rofecoxib withdrawal from the European market, the
FDA rules on post-market surveillance were criticized
and a new system of pharmacovigilance was introduced
that provided information on identified risks (Palaian
et al. 2006; Rawlins and Thompson 1981; Yadav 2008).
Throughout the early post-marketing period, the prod-
uct might be used in different groups of people from
those used in clinical trials and much larger populations
might be exposed in a relatively short time. The post-
marketing product is required to develop new informa-
tion, which can focus on the benefits as well as risks ofthe product (Arnott et al. 2012). Pharmacovigilance pro-
duces detailed information of marketed products to en-
sure their safe use.
The impressive pharmacovigilance planning can reduce
the adverse events of drugs in patients. The most import-
ant method used in pharmacovigilance is to collect infor-
mation on a drug when it is in the pre-marketing phase is
by conducting a clinical trial. This study design is not
optimum to determine the ADRs of the drug. Because in
this approach limited numbers of patients participate and
it is not necessary that the patients resemble the popula-
tion in which the drug is to be used (Arora 2008; Bahri
and Tsintis 2005), it becomes impossible to understand
the mechanism and consequence of the drug in these
groups. Some methods that can be helpful in the detection
as well as the prevention of suspected ADRs are listed as
follows.
Different study designs are included for proper phar-
macovigilance study:
a. Descriptive studies:
Descriptive studies are conducted to obtain the
outcome rate of drug use events in a specific
population. These studies include the data of adverse
events that occurred in diseased patients. Another
factor included is the drug utilization study (Biswas
and Biswas 2007; Biswas 2008). These studies
provide data on the specific groups of patients such
as children, elderly or patient with renal or hepatic
dysfunction. With these data study rates of adverse
events can be reported.
b. Analytical studies:
Analytical studies are performed to study related
outcomes of the exposure to the drug. They can
take the form of observational as well as
interventional/experimental studies. There are four
main types of analytical studies namely ecological,
cross-sectional, cohort and case–control (Brewer
and Colditz 1999).
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Observational studies provoke aspects of drug
effectiveness in patients during treatment. This is in
contrast with experiments, such as randomized
controlled trials, where each subject is
indiscriminately allocated to a treatment group or a
control group (Ciorciaro et al. 1998; Jeetu and
Anusha 2010; Joshi and Sapatnekar 2008).
Methods in pharmacovigilance for monitoring of ADR
Passive surveillance
Spontaneous reports The spontaneous reporting sys-
tems were developed after the thalidomide incident. The
aim of this spontaneous reporting system is to regulate
and control the safety of drugs. This system is applied in
the collection of post-marketing information on safety of
drugs and identification of safety signals. Consequently,
this system is used in the identification of signals of new,
rare and serious ADRs of drugs. This system makes it eas-
ier for physicians, patients and pharmacists to report sus-
pected ADRs to the pharmacovigilance centre (Herdiero
et al. 2005; Olsson 2008; Rahman et al. 2007). The phar-
macovigilance centre collects all these reports and informs
the stakeholders about the new reported ADRs. By this
method, we can monitor all drugs in the market through-
out their lifecycles (Ravindra and Vishal 2011); (Surendra
et al. 2010).
Case series The case series are applied in developing a
hypothesis between post-marketing drugs and its out-
come (Faich 1996).
Stimulated reporting
The stimulated reporting system encourages and facili-
tates health professionals to report ADRs in specific situ-
ations. It is very useful in generating adverse events of
drugs online (Gerritsen et al. 2011). It is effective in gen-
erating spontaneous reports of adverse events of drugs
identified during the post-marketing phase. This system
can assist in minimizing events by linking stimulated
reporting with early post-marketing phase (Gupta 2010).
Active surveillance
Active surveillance includes a pre-organized process to
find out more serious adverse events, including the add-
itional efforts to find the adverse reactions. Risk manage-
ment programme is followed in this process, and more
detailed information on individual adverse event reports
can be obtained compared with passive surveillance
(Panos et al. 2004; Harmark and Van Grootheest 2008;
Surendra et al. 2010; Muthiah et al. 2012; Lobo et al.
2013; Kshirsagar et al. 2011).Comparative observation studies
To test a hypothesis, a study has to be performed. These
are the key events to evaluate the adverse events. The study
can be conducted using different methods, which can be
retrospective and perspective. Major types of these studies
are cross-sectional studies, case–control studies and cohort
studies (Bates et al. 1995). Cross-sectional studies are con-
ducted for ecological analysis. These are helpful in examin-
ing the prevalence of any disease at one time point. These
studies are helpful to provide information between expos-
ure of the drug and outcome in the ecological analysis.
Case–control study can easily identify the adverse
events of drugs. The ADRs are determined by compar-
ing the two distinctive groups. Case–control studies are
useful when they are aimed to investigate adverse event
in different groups. It is helpful in determining the abso-
lute incidence rate of the adverse events.
Cohort studies provide data that has been collected in
a routine fashion. This study can also be used to exam-
ine safety issues in specific populations such as children
and patients with co-morbid conditions (Gor and Desai
2008; Hussein et al. 1999).Earmarked clinical examinations
After pre-approved clinical trials, if sufficient risks are iden-
tified, further clinical studies are done to find or evaluate
the mechanism of action for the identified adverse reac-
tions. Pharmacokinetic and pharmacodynamic studies are
applicable in determining the particular dosing, which can
cause enhanced uncertainty of adverse effects in patients.
Genetic testing can also be helpful in knowing which group
of patients might be at an increased risk of adverse reac-
tions. Children, elderly and patients with renal conditions
might metabolize drugs in a different manner compared
with patients enrolled or included in clinical trials. By these
investigations events of particular interest are focused and
used to determine or quantify the magnitude of the risk
(Surendra et al. 2010).
Thus, all of the above steps are linked with adverse
event monitoring studies. Consequently, good safety
profile of drug can be established and further suspected
adverse events can be minimized and prevented by in-
corporating the pharmacovigilance methods for adverse
drug reactions.Conclusions
ADRs have a perspective to provoke harmful effects in
patients. Health-care workers and pharmacovigilance
constrain being more conscious of perceive the ADRs in
the patient. In conclusion, this study can be useful for
physician to identify the ADRs in patients by applying
above mentioned methods.
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